Quest Partners LLC cut its holdings in Balchem Co. (NASDAQ:BCPC - Free Report) by 77.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,843 shares of the basic materials company's stock after selling 6,425 shares during the quarter. Quest Partners LLC's holdings in Balchem were worth $324,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Victory Capital Management Inc. increased its position in shares of Balchem by 129.7% in the 3rd quarter. Victory Capital Management Inc. now owns 98,853 shares of the basic materials company's stock valued at $17,398,000 after acquiring an additional 55,822 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Balchem by 32.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company's stock valued at $29,929,000 after purchasing an additional 47,036 shares during the period. Congress Asset Management Co. raised its stake in shares of Balchem by 12.4% in the third quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company's stock worth $53,053,000 after purchasing an additional 33,373 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Balchem by 2.7% during the second quarter. Conestoga Capital Advisors LLC now owns 1,155,209 shares of the basic materials company's stock worth $177,844,000 after purchasing an additional 29,825 shares during the period. Finally, Fiera Capital Corp purchased a new stake in Balchem in the third quarter valued at approximately $4,201,000. Hedge funds and other institutional investors own 87.91% of the company's stock.
Balchem Stock Performance
Shares of BCPC stock traded down $0.37 on Tuesday, hitting $182.32. The company had a trading volume of 95,248 shares, compared to its average volume of 110,322. The firm has a market cap of $5.93 billion, a P/E ratio of 48.74, a price-to-earnings-growth ratio of 5.45 and a beta of 0.65. Balchem Co. has a twelve month low of $120.87 and a twelve month high of $186.03. The company has a 50-day moving average price of $174.05 and a 200-day moving average price of $166.90. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. HC Wainwright raised their price target on shares of Balchem from $185.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, November 4th. StockNews.com raised shares of Balchem from a "hold" rating to a "buy" rating in a report on Monday, October 28th.
Check Out Our Latest Report on BCPC
Balchem Company Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
See Also
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
